Cargando…

The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives

Background: In the recent years, immunotherapeutics and specifically immune-checkpoints inhibitors have marked a significant shift in the diagnostic and therapeutic algorithm of Non-Small Cell Lung Cancer (NSCLC), allowing us to use immunotherapeutics alone or combined with chemotherapy for a great...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocco, Danilo, Gravara, Luigi D., Gridelli, Cesare
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2020
Materias:	Clinical Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497556/ https://www.ncbi.nlm.nih.gov/pubmed/31400270 http://dx.doi.org/10.2174/1574884714666190809124555

Ejemplares similares

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes
por: Rocco, Danilo, et al.
Publicado: (2023)

Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
por: Rocco, Danilo, et al.
Publicado: (2023)

The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them
por: Rocco, Danilo, et al.
Publicado: (2022)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

Immunotherapy as a targeted therapy in non-small cell lung cancer
por: Rocco, Danilo, et al.
Publicado: (2019)

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
por: Spagnuolo, Alessia, et al.
Publicado: (2023)

Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient
por: Fu, Yang, et al.
Publicado: (2022)

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
por: Dong, Jingsi, et al.
Publicado: (2019)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review
por: Spagnuolo, Alessia, et al.
Publicado: (2022)

Supportive care in patients with advanced non-small-cell lung cancer
por: Di Maio, M, et al.
Publicado: (2003)

Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies
por: Gao, Ruo-Lin, et al.
Publicado: (2022)

Critical points in the management of EGFR-mutated non-small cell lung cancer
por: Casaluce, Francesca, et al.
Publicado: (2022)

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer
por: Di Maio, M, et al.
Publicado: (2004)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer
por: Liao, Dehua, et al.
Publicado: (2022)

Bevacizumab loaded CalliSpheres® bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma
por: Liu, Haitao, et al.
Publicado: (2023)

A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges
por: Chen, Ying, et al.
Publicado: (2023)

Immunotherapy and targeted therapy for lung cancer: Current status and future perspectives
por: Zulfiqar, Bilal, et al.
Publicado: (2022)

Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer
por: Gridelli, Cesare, et al.
Publicado: (2011)

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
por: Gridelli, C, et al.
Publicado: (2003)

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
por: Lin, Li, et al.
Publicado: (2023)

Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer
por: Fu, Bingjie, et al.
Publicado: (2022)

Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor–Mutated Advanced Non-Small-Cell Lung Cancer: Case Report
por: Qin, Haifeng, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
por: Wan, Xiaomin, et al.
Publicado: (2021)

A Bibliometric Analysis of Triptolide and the Recent Advances in Treating Non–Small Cell Lung Cancer
por: Yang, Quancheng, et al.
Publicado: (2022)

Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer
por: Li, Lingling, et al.
Publicado: (2022)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

Advances in immunotherapy modalities for atherosclerosis
por: Meng, Qingwen, et al.
Publicado: (2023)

Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
por: Luo, Wenxin, et al.
Publicado: (2021)

Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance
por: Passarelli, Anna, et al.
Publicado: (2020)

Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer
por: Kurata, T, et al.
Publicado: (2004)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
por: Qiao, Liu, et al.
Publicado: (2021)

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
por: Kou, Wen, et al.
Publicado: (2022)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
por: Wang, Cong, et al.
Publicado: (2018)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
por: Jiang, Fenge, et al.
Publicado: (2022)

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients
por: Cao, Peng, et al.
Publicado: (2022)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003)

Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
por: Xiong, Anning, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t3ce350osqhvceghpoi7u55thv